Wang, Hsuan-Yuan http://orcid.org/0000-0001-9248-4281
Li, Leike
Nelson, Cody S.
Barfield, Richard
Valencia, Sarah http://orcid.org/0000-0002-8878-8407
Chan, Cliburn
Muramatsu, Hiromi http://orcid.org/0000-0003-1544-1493
Lin, Paulo J. C.
Pardi, Norbert http://orcid.org/0000-0003-1008-6242
An, Zhiqiang http://orcid.org/0000-0001-9309-2335
Weissman, Drew
Permar, Sallie R.
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (5P01AI129859)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002553)
Cancer Prevention and Research Institute of Texas (RP150551, RP190561)
Welch Foundation (AU-0042-20030616)
Article History
Received: 23 November 2022
Accepted: 30 January 2024
First Online: 20 February 2024
Competing interests
: S.R.P. serves as a consultant to Merck, Pfizer, Moderna, Dynavax, and Hoopika CMV vaccine programs and leads sponsored vaccine programs with Moderna and Merck. In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that D.W. and N.P. are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from the licensing of our patents. P.J.C.L. is an employee of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. P.J.C.L. is named on patents describing the use of modified mRNA lipid nanoparticles.